Spots Global Cancer Trial Database for bintrafusp alfa
Every month we try and update this database with for bintrafusp alfa cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer | NCT03524170 | Anatomic Stage ... Metastatic Brea... Prognostic Stag... | Bintrafusp Alfa Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| Bintrafusp Alfa Program Rollover Study | NCT05061823 | Lung Cancer Cancer | Bintrafusp alfa | 18 Years - | EMD Serono | |
| A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers | NCT04708470 | Oropharyngeal C... Neck Cancer Human Papilloma... HPV Anal Cancer Cervical Cancer Penile Cancer Vulvar Cancer Vaginal Cancer Colon Cancer | Bintrafusp Alfa NHS-IL12 Entinostat | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma | NCT04708067 | Locally Advance... Metastatic Intr... Stage III Intra... Stage IIIA Intr... Stage IIIB Intr... Stage IV Intrah... | Bintrafusp Alfa Biopsy Hypofractionate... | 18 Years - | M.D. Anderson Cancer Center | |
| Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer | NCT04220775 | Recurrent Head ... Second Primary ... | Bintrafusp Alfa Quality-of-Life... Questionnaire A... Stereotactic Bo... | 18 Years - | M.D. Anderson Cancer Center | |
| Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer | NCT04489940 | Triple Negative... | Bintrafusp alfa | 18 Years - | EMD Serono | |
| Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer | NCT04246489 | Uterine Cervica... | Bintrafusp alfa | 18 Years - | EMD Serono | |
| Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer | NCT03524170 | Anatomic Stage ... Metastatic Brea... Prognostic Stag... | Bintrafusp Alfa Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| Evaluation of Bintrafusp Alfa in Operable and Untreated Head and Neck Squamous Cell Carcinoma | NCT04428047 | Squamous Cell C... | bintrafusp alfa | 18 Years - | UNICANCER | |
| Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial | NCT04756505 | Anatomic Stage ... Hormone Recepto... Metastatic Brea... Metastatic HER2... Prognostic Stag... | Bintrafusp Alfa Immunocytokine ... Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers | NCT04708470 | Oropharyngeal C... Neck Cancer Human Papilloma... HPV Anal Cancer Cervical Cancer Penile Cancer Vulvar Cancer Vaginal Cancer Colon Cancer | Bintrafusp Alfa NHS-IL12 Entinostat | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Preoperative Bintrafusp Alfa in Operable Urothelial Carcinoma of the Bladder | NCT04878250 | Transitional Ce... Bladder Cancer | Bintrafusp alfa | 18 Years - | Queen Mary University of London | |
| Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma | NCT05005429 | Mesothelioma; L... | Bintrafusp alfa | 18 Years - | Fundación GECP | |
| TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY | NCT04481256 | Carcinoma, Squa... Oesophageal Can... | External beam r... Bintrafusp alfa Paclitaxel Carboplatin | 18 Years - | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | |
| Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma | NCT04708067 | Locally Advance... Metastatic Intr... Stage III Intra... Stage IIIA Intr... Stage IIIB Intr... Stage IV Intrah... | Bintrafusp Alfa Biopsy Hypofractionate... | 18 Years - | M.D. Anderson Cancer Center | |
| M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC) | NCT03840915 | Carcinoma, Non-... | Cisplatin Carboplatin Pemetrexed Nab-paclitaxel Gemcitabine Docetaxel M7824 Carboplatin Carboplatin Bintrafusp alfa Paclitaxel | 18 Years - | EMD Serono | |
| Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer | NCT04971187 | Locally Advance... Metastatic Lung... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... Unresectable Lu... | Bintrafusp Alfa Pemetrexed Carboplatin Cisplatin | 18 Years - | M.D. Anderson Cancer Center | |
| Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies | NCT04648826 | Sarcomas Melanomas Germ Cell Tumor... Epithelial Mali... Pulmonary Metas... | AeroEclipse II ... Bintrafusp alfa Azacytidine | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer | NCT03620201 | Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... | Bintrafusp Alfa | 18 Years - | M.D. Anderson Cancer Center | |
| Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial | NCT04756505 | Anatomic Stage ... Hormone Recepto... Metastatic Brea... Metastatic HER2... Prognostic Stag... | Bintrafusp Alfa Immunocytokine ... Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer | NCT03579472 | Anatomic Stage ... Metastatic Trip... Prognostic Stag... | Bintrafusp Alfa Eribulin Mesyla... | 18 Years - | M.D. Anderson Cancer Center | |
| Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma | NCT04708067 | Locally Advance... Metastatic Intr... Stage III Intra... Stage IIIA Intr... Stage IIIB Intr... Stage IV Intrah... | Bintrafusp Alfa Biopsy Hypofractionate... | 18 Years - | M.D. Anderson Cancer Center | |
| M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC) | NCT03631706 | Non-small Cell ... | M7824 Pembrolizumab | 18 Years - | EMD Serono | |
| First in Human Study of M6223 | NCT04457778 | Metastatic Soli... | M6223 Bintrafusp alfa M6223 | 18 Years - | EMD Serono | |
| M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC) | NCT03631706 | Non-small Cell ... | M7824 Pembrolizumab | 18 Years - | EMD Serono | |
| A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer | NCT04349280 | Neoplasms | Bintrafusp alfa | 18 Years - | GlaxoSmithKline | |
| Bintrafusp Alfa Program Rollover Study | NCT05061823 | Lung Cancer Cancer | Bintrafusp alfa | 18 Years - | EMD Serono | |
| Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma | NCT05005429 | Mesothelioma; L... | Bintrafusp alfa | 18 Years - | Fundación GECP | |
| Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046) | NCT04551950 | Cervical Cancer | M7824 Carboplatin Paclitaxel Bevacizumab Cisplatin Radiotherapy | 18 Years - | EMD Serono | |
| Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC | NCT04066491 | Biliary Tract C... Cholangiocarcin... Gallbladder Can... | M7824 Placebo Gemcitabine Cisplatin | 18 Years - | EMD Serono | |
| Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer | NCT04246489 | Uterine Cervica... | Bintrafusp alfa | 18 Years - | EMD Serono | |
| Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer | NCT04489940 | Triple Negative... | Bintrafusp alfa | 18 Years - | EMD Serono | |
| Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma | NCT05005429 | Mesothelioma; L... | Bintrafusp alfa | 18 Years - | Fundación GECP | |
| M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer | NCT03620201 | Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... | Bintrafusp Alfa | 18 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
